Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel (Cardionovum)
- Development stage
- Unknown
- Lead developer
- Cardionovum
- Modality
- Small Molecules
- Administration
- Intra-arterial
01
Overview
Paclitaxel is a small molecule microtubule-stabilizing agent that serves as the anti-proliferative component of the Legflow drug-coated balloon (DCB), developed by Cardionovum GmbH for the treatment of peripheral artery disease (PAD). The Legflow device utilizes the proprietary SAFEPax coating technology, which consists of a lipophilic matrix of paclitaxel and an ammonium salt excipient. This coating is designed to facilitate the rapid and efficient transfer of paclitaxel into the arterial wall during balloon inflation. Once in the tissue, paclitaxel binds to the beta-subunit of tubulin, promoting microtubule assembly and preventing disassembly. This action arrests the cell cycle in the G2/M phase, effectively inhibiting the proliferation and migration of vascular smooth muscle cells, which are the primary drivers of neointimal hyperplasia and restenosis following balloon angioplasty. The MAGNIFICENT trial demonstrated the efficacy and safety of the Legflow DCB compared to plain old balloon angioplasty (POBA) in treating atherosclerotic lesions in the superficial femoral and popliteal arteries.
- Brand names
- Legflow
- Other names
- paclitaxel-coated balloonLegflow DCB
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel (Cardionovum).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel (Cardionovum).